GE Healthcare assists CBMG accelerate cell therapy manufacturing: 5 insights

Written by Mackenzie Garrity | January 19, 2018 | Print  |

Cellular Biomedicine Group partnered with GE Healthcare to accelerate its stem cell therapy manufacturing timeline.

Here are five insights:


1. CBMG’s facility in Shanghai, China, will utilize GE Healthcare’s FlexFactory platform, which is designed to speed up the manufacturing process for cell therapy clinical trials and commercial launches.


2. GE Healthcare developed FlexFactory as a semi-automated end-to-end platform. Getting a lab ready for industrial-scale manufacturing takes around nine months using the platform. The typical timeline can reach close to two years.


3. CBMG is the first company to install the FlexFactory for cell therapy, and it expects its facility to be up and running by the end of 2018.


4. In addition to development support, the FlexFactory will provide CBMG development and training services, cell processing equipment, semi-automation capabilities and digital connectivity solutions.


5. GE Healthcare works with the Centre for Commercialization of Regenerative Medicine to provide consumers development services, including cell technologies and protocol experts.


More articles on biologics:
Major breakthroughs in spinal biologics, disc regeneration on the horizon: 3 key thoughts from Dr. William Watters
Mayo Clinic receives FDA approval for stem cell reproduction system: 5 insights
ORTHOReBIRTH USA receives FDA clearance for ReBOSSIS: 5 highlights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months